GAMMA Investing LLC Boosts Holdings in Repligen Co. (NASDAQ:RGEN)

GAMMA Investing LLC raised its stake in Repligen Co. (NASDAQ:RGEN - Free Report) by 17,721.1% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 121,896 shares of the biotechnology company's stock after buying an additional 121,212 shares during the quarter. GAMMA Investing LLC owned about 0.22% of Repligen worth $15,510,000 at the end of the most recent quarter.

A number of other institutional investors have also made changes to their positions in the stock. Polar Asset Management Partners Inc. lifted its holdings in shares of Repligen by 76.9% in the 4th quarter. Polar Asset Management Partners Inc. now owns 6,900 shares of the biotechnology company's stock worth $993,000 after acquiring an additional 3,000 shares during the last quarter. GTS Securities LLC acquired a new position in Repligen during the fourth quarter worth $264,000. Gordian Capital Singapore Pte Ltd purchased a new position in shares of Repligen during the fourth quarter worth $259,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its stake in shares of Repligen by 12.8% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 235,343 shares of the biotechnology company's stock valued at $33,875,000 after buying an additional 26,733 shares in the last quarter. Finally, Two Sigma Advisers LP grew its stake in shares of Repligen by 6.7% in the fourth quarter. Two Sigma Advisers LP now owns 134,800 shares of the biotechnology company's stock valued at $19,403,000 after buying an additional 8,500 shares in the last quarter. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Repligen

In related news, Director Margaret Pax purchased 250 shares of the stock in a transaction that occurred on Monday, March 17th. The shares were purchased at an average price of $150.69 per share, with a total value of $37,672.50. Following the completion of the acquisition, the director now directly owns 1,043 shares in the company, valued at $157,169.67. This represents a 31.53% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 1.20% of the company's stock.

Repligen Stock Performance

NASDAQ RGEN traded up $1.19 during trading hours on Tuesday, hitting $132.87. The company had a trading volume of 630,969 shares, compared to its average volume of 747,981. The business has a 50 day moving average of $127.51 and a 200-day moving average of $143.27. The company has a market cap of $7.47 billion, a PE ratio of -260.53, a price-to-earnings-growth ratio of 4.54 and a beta of 1.10. Repligen Co. has a 1-year low of $102.97 and a 1-year high of $182.52. The company has a debt-to-equity ratio of 0.26, a quick ratio of 8.76 and a current ratio of 10.44.

Repligen (NASDAQ:RGEN - Get Free Report) last posted its earnings results on Tuesday, April 29th. The biotechnology company reported $0.39 earnings per share for the quarter, beating the consensus estimate of $0.35 by $0.04. The business had revenue of $169.17 million during the quarter, compared to the consensus estimate of $163.65 million. Repligen had a positive return on equity of 4.21% and a negative net margin of 4.64%. The business's quarterly revenue was up 10.4% on a year-over-year basis. During the same period in the previous year, the business earned $0.28 EPS. As a group, equities research analysts expect that Repligen Co. will post 1.72 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research firms recently issued reports on RGEN. JPMorgan Chase & Co. decreased their target price on Repligen from $200.00 to $190.00 and set an "overweight" rating on the stock in a research note on Tuesday, April 29th. HC Wainwright reissued a "buy" rating and set a $180.00 price target on shares of Repligen in a research report on Monday, May 5th. Wolfe Research raised Repligen from a "peer perform" rating to an "outperform" rating and set a $160.00 price target on the stock in a research report on Tuesday, April 29th. Evercore ISI started coverage on shares of Repligen in a report on Tuesday, March 18th. They issued an "in-line" rating and a $155.00 price objective on the stock. Finally, TD Cowen began coverage on shares of Repligen in a research report on Monday, February 10th. They set a "buy" rating and a $200.00 price objective for the company. Six research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company's stock. According to MarketBeat.com, Repligen has an average rating of "Moderate Buy" and an average price target of $173.25.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.